In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. September 19, 2019

    Jury's Task In Ohio Opioid MDL Trial Divides Drug Cos.

    Drug companies involved in multidistrict opioid litigation voiced divergent views in Ohio federal court Thursday on the jury's role in a looming bellwether trial, a question with significant implications for a potential multibillion-dollar remedy.

  2. September 18, 2019

    Opioid 'Negotiation Class' Justifies DQ Bid, Distributors Say

    Drug distributors and pharmacies continued to press their surprise effort to disqualify the judge overseeing the opioid multidistrict litigation, saying his recent approval of a novel negotiation class merits their last-minute play.

  3. September 16, 2019

    4 Key Takeaways As Opioid MDL Distributors Seek Judge's DQ

    An out-of-the-blue crusade by drug distributors and pharmacies to disqualify the judge supervising multidistrict opioid litigation has little chance of succeeding, but it could lay the foundation for future challenges to the judge's sweeping rejection of legal defenses, experts say. Here, Law360 explores four key takeaways about the motion's impetus and likely fate.

  4. September 16, 2019

    Opioid MDL Cos. Accused Of 'Inventing' Comments By Judge

    Attorneys for local governments on Monday accused drug distributors and pharmacies of "inventing" statements by U.S. District Judge Dan Aaron Polster in order to make him appear biased, urging the court to reject the companies' disqualification bid.

  5. September 14, 2019

    Opioid MDL Judge Deserves DQ For Bias, Distributors Say

    Drug distributors and pharmacies on Saturday launched a bold attack on the Ohio federal judge supervising multidistrict opioid litigation, accusing him of appearing deeply biased against them and deserving of disqualification.

  6. September 13, 2019

    Meet The Attys Leading The Opioid MDL 'Negotiation Class'

    A team of six top attorneys will now be representing a novel “negotiation class" on behalf of cities and counties in the opioid multidistrict litigation with the hopes of hammering out a global settlement with opioid manufacturers and distributors accused of fueling the devastating epidemic. Here are the six negotiators and some of their biggest cases and notable achievements.

  7. September 11, 2019

    6th Circ. Won't Reinstate DQ'd BakerHostetler In Opioid MDL

    The Sixth Circuit has rejected a bid by two Endo units to order an Ohio federal court to vacate its order disqualifying a former U.S. attorney and her firm BakerHostetler from representing the companies in sprawling Ohio multidistrict litigation involving racketeering and corrupt practices charges against various opioid makers and distributors.

  8. September 11, 2019

    Opioid MDL 'Negotiation Class' Wins Approval

    In a possible turning point for a wave of opioid-crisis lawsuits, an Ohio federal judge on Wednesday approved a novel "negotiation class" that could encompass every U.S. city and county in hopes of striking global settlements with pharmaceutical companies.

  9. September 11, 2019

    Purdue To Settle Thousands Of Opioid Suits, File Bankruptcy

    Purdue Pharma LP and its owners, the Sackler family, have reached a tentative deal to settle roughly 2,000 opioid suits brought by local governments, states and tribes, with the Sacklers agreeing to pay $3 billion from their own fortune, a source involved with the negotiations told Law360 on Wednesday.

  10. September 10, 2019

    Purdue, Opioid Distributors Can't Dodge RICO Claims In MDL

    Purdue Pharma and other opioid makers and distributors can't avoid racketeering and corrupt practices charges in sprawling Ohio multidistrict litigation because the suing cities and Native nations have plausibly alleged the companies "associated together for the common purpose of expanding the prescription opioid market," a federal judge ruled Tuesday.